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Despite  exciting  advances  in targeted  therapies,  high  drug  costs,  marginal  therapeutic  beneﬁts  and
notable  toxicities  are  concerning  aspects  of  today’s  cancer  treatments.  This  special  issue of Seminars
in  Cancer  Biology  proposes  a broad-spectrum,  integrative  therapeutic  model  to  complement  targeted
therapies.  Based  on extensive  reviews  of  the  cancer  hallmarks,  this  model  selects  multiple  high-priority
targets  for  each  hallmark,  to  be approached  with  combinations  of low-toxicity,  low-cost  therapeutics,
including  phytochemicals,  adapted  to the  well-known  complexity  and  heterogeneity  of malignancy.  A
global  consortium  of  researchers  has  been  assembled  to advance  this  concept,  which  is  especially  rele-
vant  in an  era of rapidly  expanding  capacity  for genomic  tumor  analyses,  alongside  alarming  growth  in
cancer  morbidity  and mortality  in low-  and  middle-income  nations.
© 2015  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC BY-NC-ND  license  (http://. Introduction
Targeted therapies, immunotherapy and precision medicine
re coming to dominate oncology practice and research. From
he early targeted therapies, such as trastuzumab and beva-
izumab, to the newest United States Food and Drug Administration
USFDA)-approved immunotherapies, this paradigm has registered
ajor achievements. The early tyrosine kinase inhibitor imatinib
as converted some formerly fatal leukemias to medically man-
geable conditions [1]. The CLEOPATRA trial added pertuzumab
o a control regimen of trastuzumab–docetaxel and recorded a
5.7 month increase in survival [2]. Immunotherapies, including
embrolizumab, nivolumab and ipilimumab, singly and in com-
ination, are driving survivals higher in devastating melanomas
nd lung cancers [3,4]. All these advances are cause for celebra-
ion for clinicians, researchers and companies gaining approval
or life-prolonging therapies. But a problem dogs the paradigm:
herapeutic resistance is common, and often discouragingly rapid
n onset. Driven by the inherent heterogeneity of cancers, resis-
ance too often leaves single-target strategies with diminished
fﬁcacy, and overall survival is limited or not improved at all. Most
elanoma patients treated with BRAF or MEK  inhibitors relapse
fter 5–7 months [5]. Bevacizumab is typically added to chemother-
py regimens in colorectal cancer, but pivotal trials recorded
ncreases in overall survival of only 4.7 months in ﬁrst-line and
.2 months in previously-treated patients [6]. Other second-line
reatments, such as ramucirumab in gastric cancers [7] show simi-
arly limited improvements in survival. Even the overall survival
f 25 months recorded for a dafratinib–trametinib combination
or metastatic melanoma must seem cruelly short to the recently
ttp://dx.doi.org/10.1016/j.semcancer.2015.08.002
044-579X/© 2015 Elsevier Ltd. This is an open access article under the CC BY-NC-ND liccreativecommons.org/licenses/by-nc-nd/4.0/).
diagnosed sufferer [8]. We  have a long way  to go before oncology
can offer true comfort to most patients.
Multiple factors contribute to therapeutic resistance. Genomic
instability results in genetically heterogeneous tumors, typi-
cally with 40–80 mutations per patient [9]. Selection pressures
from a targeted therapy can result in evolutionary expansion of
treatment-resistant clones already existing in the tumor. Other
resistance mechanisms arise separately from the therapeutic tar-
get. These include, for instance, dysregulation of pro-apoptotic
proteins, enhancement of DNA repair, and interactions with a
tumor microenvironment that may  shelter quiescent tumor cells
as they develop resistant phenotypes.
The high costs of targeted therapies are well known. Most of the
drugs approved in 2012 by the USFDA cost more than $100,000 per
year per patient, perhaps not a surprise in view of the accelerating
costs of drug development, which reached $1.8 billion for research
and approval in recent years [10]. Clinicians drew attention to
these high costs in 2013, when more than 100 experts in chronic
myeloid leukemia called for lower prices and broader access to
these drugs in the journal Blood [11]. A 2015 presentation at the
American Society for Clinical Oncology estimated the yearly cost of
combination immunotherapy at $1 million per patient [12]. Even
bevacizumab, now standard of care in colon cancer, was recently
found in a cost-effectiveness analysis to offer minimal beneﬁt and
high cost when taking into account the short survival increment
it confers [13]. Moreover, at least half of cancer cases and mortal-
ity are now known to occur in low- and middle-income countries
[14]. The World Health Organization recommends that the yearly
cost of a drug should be no more than three times the average per
capita income in a country to be considered cost-effective [15]. In
ense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ow- to middle-income countries with per capita incomes ran-
ing from $1045 to $12,746 in 2015 [16], costs for treatment
eaching six-ﬁgure levels are unsustainable. Exploring lower-cost
lternatives to high-cost therapies, speciﬁcally alternatives that
ay  reduce therapeutic resistance through a broad-spectrum
pproach that seeks therapies with radically expanded sets of tar-
ets, is the goal of this special issue of Seminars in Cancer Biology.
. Expanding our options: Exploring the rationale for a
road-spectrum approach
A broad-spectrum approach to cancer is one that addresses mul-
iple pathways and targets relevant to prevention and therapy of
alignancy, similar to the use of broad-spectrum antibiotics that
ill multiple bacterial species. The select broad-spectrum concept
resented in this special issue focuses on using a combination of
gents to affect a broad range of relevant cancer-speciﬁc targets.
hy consider such an approach in the face of the undeniable,
lbeit still limited, success of the targeted therapy paradigm? The
ajor reason for considering this approach, which we propose as a
omplement rather than a replacement of targeted pharmaceutical
herapies, is the problem of resistance to therapy. The complex-
ty and heterogeneity of cancer in both preventive and therapeutic
ettings leads to resistance as clonal evolution under the selective
ressure from narrowly targeted therapies implacably proceeds [9].
ombination therapies have long been recognized as a means to
hwart resistance, leading to the widespread use of combination
hemotherapy. Combining targeted therapies or immunotherapies
an be effective [2,3]. However, ineffective combinations with ele-
ated toxicity are often seen, and even successful immunotherapies
ave recorded rates of severe adverse events of over 50% [17–19].
Hepatocellular carcinoma (HCC), which occurs most commonly
n less-developed countries, exempliﬁes the need for a broad-
pectrum approach. HCC develops in the complex environment
f the liver. Factors like alcohol and hepatitis infection induce
mmune-mediated inﬂammation, virally-mediated oncogenesis,
utations due to oxidative stress, and epigenetic damage in mul-
iple cell types [20]. Expression of angiogenic factors by tumor
tromal cells begins early in carcinogenesis. Stromal cells secrete
nﬂammatory mediators and cytokines associated with metastasis.
ancer-promoting immune cells exert multiple detrimental effects.
n this complex setting, especially in more advanced disease, tar-
eting one signaling pathway results in selective pressures for
lones responding to other stimulatory pathways [9]. And indeed,
esponse to the standard-of-care sorafenib for advanced disease is
odest [21]. Intervening with a broad-spectrum approach using
ow-cost and low-toxicity therapies may  address the multiple
efects of this tumor and its microenvironment.
. The hallmarks of cancer: Framing the broad-spectrum
oncept and integrative stance
The complexity and heterogeneity of cancer have been rec-
gnized by many. Vogelstein and colleagues [22], for instance,
escribe 12 major signaling pathways relevant to cancer growth
nd 138 “driver” genes considered most important in onco-
enesis. Block [23] proposes a broad-spectrum framework based
n the insights of integrative medicine. Host environmental factors,
ermed “terrain factors”, such as inﬂammation, oxidation, immune
egulation and glycemia, can be modulated by diet, exercise,
ind-body medicine and carefully selected nutraceuticals. Twelveumor-based “pathways of progression” also must be addressed,
mong them resistance to apoptosis, metastasis and cell-to-cell
ommunication. Interventions like dietary change and exercise
re inherently multi-targeted, and may  reduce, for instance,iology 35 (2015) S1–S4
inﬂammatory signaling or glycemic imbalance in a multi-faceted
way [24]. They thus form a foundation for the clinical application
of broad-spectrum approaches.
The conceptual framework selected for this exploration of
broad-spectrum therapeutics is that of the cancer hallmarks. These
were described by Hanahan and Weinberg [25], who proposed
6 hallmarks in 2000. They added two more hallmarks and two
enabling characteristics in 2011 [26]. The concept of the cancer hall-
marks is now widely recognized and inﬂuential. For the purposes of
this project, we  will treat both the hallmarks and the enabling char-
acteristics as hallmarks of malignancy. We  have also added an 11th
characteristic that we will treat as a hallmark, the tumor microen-
vironment. The signiﬁcance of the microenvironment is evident in
the description of HCC above, but extends through many cancer
types and is increasingly viewed as a critical setting for therapeutic
targets [27].
The clinical message of the cancer hallmarks and our broad-
spectrum design for cancer treatment is that we must broaden
our concept of the “actionable target” for a therapeutic inter-
vention, not simply relying on a limited set of molecular or
immunologic targets with a correspondingly limited set of drug
therapies. The rapid expansion of genetic testing enables us to
obtain multi-faceted genetic proﬁles of tumors. Using such proﬁles,
broad-spectrum approaches can and should be constructed that
override the constraints of the existing single-target intervention
model of treatment.
4. Getting to know cancer: The Halifax Project
The model of a broad-spectrum cancer therapy based on
combination of low-cost, low-toxicity agents aimed at multiple
therapeutic targets was independently introduced by Block in the
volume Life Over Cancer [23], and by a non-proﬁt organization,
Getting To Know Cancer (GTKC). An initiative called the Halifax
Project, organized by GTKC, undertook a project to assemble a set
of reviews on the 11 cancer hallmarks, authored by an interna-
tional team of experienced research scientists. These reviews are
published in this special issue of Seminars in Cancer Biology. Each
review summarizes one hallmark, explains the carcinogenic dys-
functions it involves, assesses its relation to other hallmarks, and
suggests a set of potential drug targets and therapeutic approaches.
The broad-spectrum model is then summarized in a capstone
paper [28]. The approaches emphasize low-toxicity and low-cost
agents, including phytochemicals, preferring those without current
intellectual property protection so that broad-spectrum thera-
pies composed of combinations of these agents would be widely
accessible globally. Recognizing the network of signaling pathways
involved in malignant processes [29,30], the project implemented
a cross-validation literature review to help evaluate targets and
approaches. This accounts for the possibility that manipulating one
target, or exploiting one therapeutic approach, may have a car-
cinogenic or tumor-stimulating effect on another cancer hallmark.
Tables of cross-validations are found in the hallmark reviews.
5. The hallmark reviews
The ﬁrst hallmark, genomic instability, provides the basic means
for a cell to gain selective growth advantages over its neighbors.
As Christopher Maxwell and his team show, the ﬁdelity of the
genome, maintained by a series of checkpoints, is breached in can-
cer. This results in genetically and epigenetically heterogeneous
malignancies that proliferate under selective pressures, resulting in
cancer’s adaptability and therapeutic resistance. They propose ﬁve
targets for improving cancer prevention and therapy: prevention of
DNA damage, enhancement of DNA repair, targeting deﬁcient DNA
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epair, impairing centrosome clustering, and inhibition of telome-
ase activity.
Abnormal cell proliferation represents an important feature of
ancer development and progression. Various signaling mecha-
isms are involved in uncontrolled cancer cell proliferation. The
rticle by Mark Feitelson and colleagues highlights some of the
idely studied targets in several pathways that regulate prolifera-
ion, such as hypoxia inducible factor 1, nuclear factor -B (NF-B),
hosphoinositide 3-kinase/protein kinase B (PI3K/Akt), insulin-like
rowth factor receptor 1, Wnt/-catenin, cell cycle-associated pro-
eins as well as androgen and estrogen receptor signaling.
The evasion of anti-growth signaling is an essential characteris-
ic of cancer cells. In order to sustain proliferation, neoplastic cells
ust uncouple themselves from numerous signals that are known
o slow down cellular growth. The article contributed by Dong
hin and his group eloquently describes the anti-growth signaling
rocess and reviews several important pathways involved in
rowth signaling, namely p53, phosphatase and tensin homolog,
etinoblastoma protein, Hippo, growth differentiation factor 15,
T-rich interactive domain 1A, Notch, insulin-like growth factor
nd Krüppel-like factor 5 pathways.
Ramzi Mohammad and colleagues describe various factors
hich contribute to apoptosis resistance in cancer. Apoptosis or
rogramed cell death represents an endogenous process of remov-
ng defective cells from the body. Nevertheless, deregulation of
poptotic signaling facilitates cancer cells to escape this process,
eading to uncontrolled proliferation resulting in tumor cell sur-
ival, drug resistance and recurrence of the disease. This article
ocuses on key resistance targets, namely Bcl-2 and Mcl-1 proteins,
utophagy, necrosis and necroptosis, heat shock protein signaling,
roteasome pathway, epigenetic mechanisms and aberrant nuclear
xport signaling.
Replicative immortality allows transformed cells to con-
inuously self-renew, accumulating mutations that promote
nvasiveness and therapeutic resistance. Paul Yaswen and col-
eagues explore the use of senescence-inducing therapies that
esult in growth arrest. Consideration is given to the role of tel-
merase and to the search for agents promoting stable senescence.
 number of potential targets are singled out for further research,
ncluding telomerase, human telomerase reverse transcriptase,
ammalian target of rapamycin, cyclin-dependent kinase (CDK)
/6, CDK 1/2/5/9, PI3K and Akt.
Dysregulated metabolism in cancer, often called the “Warburg
ffect”, revolves around the reprogramed metabolic state of many
ancer cells, allowing them to turn energy production toward
iosynthesis and growth. Matthew Hirschey and colleagues
oint out hexokinase-2,6-phosphofructo-2-kinase/fructose-
,4,biphosphatase and pyruvate kinase isoform M2  as important
egulators of glycolysis in cancer cells. In addition to altered glu-
ose metabolism, glutamine oxidation is emerging as an attractive
herapeutic target. Studies of targets for dysregulated metabolism
re still preliminary but represent an exciting new area of cancer
iology.
Chronic inﬂammation is linked to various phases of tumorigen-
sis, including transformation, apoptosis, invasion, angiogenesis
nd metastasis. Leroy Lowe and his team explore targeting
f these effects in malignancy. They discuss the multi-faceted
elationship of immunity and chronic inﬂammation in cancer.
acrophage migration inhibitory factor, cyclooxygenase-2, NF-B,
umor necrosis factor-,  inducible nitric oxide synthase, Akt, and
hemokines are important anti-inﬂammatory targets that might be
uitable for a multi-pronged therapeutic approach.Immune evasion by tumors is accomplished by several mech-
nisms including generating regulatory cells, defective antigen
resentation, immune suppressive mediators, apoptosis, toler-
nce and immune deviation. Byoung Kwon and colleagues reviewiology 35 (2015) S1–S4 S3
the exciting work now emerging in this area. A broad-spectrum
approach suggests use of nonspeciﬁc immune enhancers, target-
ing Th-1 responses, enhancing  T cells, activating macrophages,
inhibiting Treg lymphocytes, induction of interleukin-2 and
enhancing natural killer cells.
Microenvironment has been postulated as a cause as well
consequence of tumorigenesis, inﬂuencing cellular proliferation,
growth, metabolism, angiogenesis, hypoxia and innate and ada-
pative immunity. Dean Felsher and his group elegantly describe
how cholesterol synthesis and metabolites, reactive oxygen species
and hypoxia, macrophage activation and conversion, indoleamine
2,3-dioxygenase regulation, vascular endothelial growth factor,
ﬁbrosis, as well as endoglin and Janus kinase signaling emerge as
pivotal links in the regulation of tumorigenesis.
Angiogenesis – the growth of new blood vessels from an
existing vasculature – is considered to be an essential patho-
logic feature of cancer and inhibition of tumor angiogenesis
has become an important anti-cancer therapeutic strategy. Lasse
Jensen and co-researchers identify 10 important aspects of tumor
angiogenesis as targets for anti-angiogenic therapy. These include
inhibiting endothelial cell migration/tip cell formation, reduc-
ing structural abnormalities of tumor vessels, reducing hypoxia,
inhibiting lymphangiogenesis, reducing elevated interstitial ﬂuid
pressure, reversing poor perfusion, normalizing disrupted cir-
cadian rhythms, suppressing tumor-promoting inﬂammation,
deactivating tumor-promoting ﬁbroblasts and normalizing tumor
cell metabolism/acidosis.
Understanding of the key clinical issue of cancer metastasis is
still evolving. Establishment of the invasive phenotype, the inva-
sive process itself, tumor establishment at secondary sites and the
interaction between cancerous and non-cancerous cells play key
roles in the complex cascade of metastatic dissemination. Fac-
tors explored by Wen  Jiang and colleagues comprise disruption
of E-cadherin and tight junctions, key signaling pathways, includ-
ing urokinase-type plasminogen activator, PI3K/Akt, focal adhesion
kinase, -catenin/zinc ﬁnger E-box-binding homeobox 1 and trans-
forming growth factor-,  together with inactivation of activator
protein 1 and suppression of matrix metalloproteinase-9 activity.
We conclude this editorial with the hope that this special issue
containing articles by our esteemed colleagues dedicated to discov-
ering a successful means of managing cancer through an innovative
new model represents a critical, effective and more sustainable
effort in our ﬁght against malignant disease. We believe that these
contributions provide both resource and inspiration to the reader
that a broad-spectrum integrative strategy may  be our best hope
to combat cancer.
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